Epithelial Ovarian Cancer

Senescent PFB exosomes promoted migration and upregulated CCL11, TGF-β1, BIRC5, and CHEK1. These findings suggest that therapy-induced senescence in peritoneal cells may contribute to EOC recurrence by reactivating dormant tumor cells through exosomal signaling.

P1/2, N=69, Completed, Cybrexa Therapeutics | Active, not recruiting --> Completed | N=130 --> 69 | Trial primary completion date: Mar 2025 --> Jun 2025

Emphasis is placed on optimal sample selection, validated techniques, and multidisciplinary integration is required to ensure diagnostic quality. These recommendations aim to optimize prognostic stratification and guide personalized treatment strategies, ultimately improving clinical outcomes in ovarian cancer.

Importantly, pharmacological induction of ferroptosis using RSL3 abolished the tumour-promoting effects of CEVs, demonstrating that ferroptosis suppression is essential for CEVs-mediated tumour progression. Collectively, our findings identify bacterial extracellular vesicles as functional modulators of host redox metabolism and ferroptosis, revealing a previously unrecognized mechanism by which tumour-associated microbiota influence cancer progression.

P2, N=40, Recruiting, University Hospital, Linkoeping | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Sensitivity and specificity of HE 4 was 75% and 60% each. Higher levels of HE4 and CA125 were observed in patients with deep myometrial invasion and higher grade of tumor.

In summary, our study establishes the comprehensive molecular atlas and a targeted therapeutic subtyping framework, revealing therapeutic vulnerabilities and providing novel insights for advancing precision oncology in OCCC management.

P1/2, N=150, Recruiting, InxMed (Shanghai) Co., Ltd. | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> May 2026

P3, N=1367, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

Targeting ST3Gal1-mediated α2,3-sialylation disrupts VEGF-R2 signaling and suppresses metastatic behavior in E-OC models. Although clinical associations suggest a potential link with adverse outcomes, larger studies are required to clarify its independent prognostic significance. Combined inhibition of ST3Gal1 and VEGF-R2 reduced tumor growth in vivo; these findings support further investigations of ST3Gal1 as a potential therapeutic target in E-OC.

This study aims to address whether simultaneously targeting CTH and mTOR could enhance therapeutic outcomes beyond those achieved by mTOR inhibition alone.CCOC lines were engineered with CTH knockout (KO) or treated with the CTH inhibitor Aviglycine hydrochloride (AVG; ABG-3168); mTOR was blocked with everolimus, a clinical stage mTOR inhibitor...In CTH-deficient models, the synergy was maintained; however, pharmacological inhibition of CTH with AVG did not produce additional effects, indicating dependence on CTH activity and supporting an on-target mechanism. Similar antiproliferative effects with combined treatment were observed in a CTH-expressing Ewing sarcoma (EwS) model.Together, these findings support biomarker-guided strategies and rational combination therapies that achieve dual targeting of mTOR and CTH, thereby disrupting protein translation and hypoxia adaptation in CCOC and other CTH-expressing cancers.